Pharmacokinetics of lipid-bound and liberated amphotericin B (AMB) was assessed in eleven 28 critically ill patients with cholestatic liver disease (CSLD) and in nine with normal liver 29 function treated with AMB colloidal dispersion (ABCD). Exposure to lipid-bound AMB was 30 higher in patients with CSLD. Levels of liberated AMB were elevated by CSLD only after the first 31 dose whereas its pharmacokinetics was unaffected at steady state. The study was approved by the local ethics committee. Time-AMB-concentration profiles 48 were determined in critically ill patients with CSLD (plasma bilirubin > 10 mg/dl due to 49 CSLD) and in a control group comprising critically ill patients with approximately normal 50 hepatic function (bilirubin < 1.28 mg/dl). Patients with a plasma bilirubin level between 1.28 51 and 10 mg/dl and patients with a plasma bilirubin level > 10 mg/dl caused by disorders other 52 than CSLD (e. g. hemolysis) were excluded from the study. ABCD was administered for 53 suspected or proven IFIs over 4 hours at a dose of ~4 mg/kg. In order to avoid infusion-54 related toxicity, ~2 mg/kg were given on day 1. In all patients enrolled, conventional AMB 55 deoxycholate was contraindicated because of its renal toxicity. Blood samples of 2 ml were 56 taken from an arterial line on day 1 of ABCD therapy (single-dose) and on day 5 or later 57 Fifteen and ten data sets were obtained from patients with CSLD and from the control group, 71 respectively ( Table 1, Table 2 ). In the control group, AMB steady-state pharmacokinetics was 72 comparable to previous data (3). Lipid-bound AMB displayed significantly higher peak 73 concentrations and AUC 0-24 values in the CSLD group (Figure 1, Table 3 ). Its clearance was 74 delayed by ~90%, and the volume of distribution (V d ) was reduced by ~50% in patients with 75 CSLD. Levels of liberated AMB were higher and its V d was significantly smaller in CSLD 76 patients after administration of the first dose. V d inversely correlated with the Child-Pugh-77 score. Steady state pharmacokinetics of liberated AMB, however, was similar within the two 78 groups. Pharmacokinetics of total AMB resembled that of liberated AMB (Table 3) . Table 4  79 compares AMB pharmacokinetics in cirrhosis and in CSLD associated with hematologic 80 disease. 81
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Liver disease has been identified as a risk factor for invasive fungal infections (IFIs) such as 35 invasive aspergillosis in critically ill patients (15, 16) . Amphotericin B (AMB) has a broad 36 antimycotic spectrum and is therefore a cornerstone in treatment of IFIs. Because of its renal 37 toxicity, however, conventional AMB is frequently replaced by less toxic lipid-formulations 38 such as AMB colloidal dispersion (ABCD, Amphocil ® , Amphotec ® ). ABCD contains AMB 39 as a cholesteryl sulphate complex forming disc-like structures of 74-170 nm in diameter (5). 40 AMB does not undergo hepatic metabolism, but it is eliminated in part via the bile. ABCD is 41 rapidly taken up by liver macrophages (11, 25) . Clinical studies on the influence of hepatic 42 impairment on AMB pharmacokinetics are lacking so far. Therefore, pharmacokinetics of 43 lipid-bound (colloidal) AMB and of AMB liberated from its lipid-binding was assessed under 44 single-dose and steady-state conditions in critically-ill patients with and without cholestatic 45 liver disease (CSLD) treated with ABCD. 46
47
The study was approved by the local ethics committee. Time-AMB-concentration profiles 6/21 impairment (19) . A slightly reduced exposure to anidulafungin and micafungin was observed 110 in patients with severe and moderate liver dysfunction, respectively. Nevertheless, no dose 111 adjustment is recommended when anidulafungin or micafungin is administered to this group 112 of patients (8, 13) . 113 114 In conclusion, steady-state pharmacokinetics of liberated, active AMB appears to be largely 115 un-influenced by CSLD in patients treated with ABCD and standard dosage will probably be 116 Legend to Tables:  218   TABLE 1 Table 1 ). *The 283 difference between the patients with liver cirrhosis and patients with CSLD associated with 284 hematologic disease was significant (P<0.05). Data is displayed as mean ± standard deviation. 
